Analyst firms · Morgan Stanley · ADGI

Morgan Stanley ADGI price target and rating history

Adagio Therapeutics Inc. (ADGI) · Health Care

Morgan Stanley rates Adagio Therapeutics Inc. (ADGI) Underweight with a $6 price target, as of its latest action on Jan 6, 2022. It has published 5 rating actions on ADGI since August 2021, including 1 upgrade and 3 downgrades.

Current rating
Underweight
Price target
$6
Median target, all firms
Too few
Actions on ADGI
5

Morgan Stanley price target on ADGI

$49$28$620222023202420252026
Morgan Stanley price target on ADGI, each point a stated target, August 2021 to January 2022.

Every Morgan Stanley rating on ADGI

Questions about Morgan Stanley and ADGI

What is Morgan Stanley's price target for ADGI?
Morgan Stanley's latest stated price target for Adagio Therapeutics Inc. (ADGI) is $6, from its action on Jan 6, 2022.
What is Morgan Stanley's rating on ADGI?
Morgan Stanley rates ADGI Underweight, a bearish rating, as of Jan 6, 2022.
When did Morgan Stanley last change its view on ADGI?
On Jan 6, 2022, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $11 to $6.

All Morgan Stanley ratingsADGI news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.